Hainan Shuangcheng Pharmaceuticals Co Ltd

Hainan Shuangcheng Pharmaceuticals Co Ltd has a market capitalization of 4.77 billion CNY and a price-to-earnings ratio of 250.43, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 11.56, suggesting that the market is valuing its equity significantly above its book value. The enterprise value to EBITDA ratio is 573.44, which is extremely high and implies that the company is being valued at a premium relative to its earnings before interest, taxes, depreciation, and amortization. The company's liquidity position is assessed as medium, with a current ratio of 0.67, indicating that it has less than one CNY in current assets for every CNY in current liabilities.

The company's profitability is modest, with a return on equity of 4.62% and a return on assets of 2.31%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The net income of 19.04 million CNY is relatively low compared to the company's total assets of 825.78 million CNY, suggesting that the company is not generating significant returns on its asset base. The gross profit margin is 53.83%, which is in line with industry norms, but the operating margin of 3.14% is relatively low, indicating that the company is facing significant operating expenses.

Hainan Shuangcheng Pharmaceuticals Co Ltd operates primarily in the domestic market, with no disclosed international revenue segments. The company's revenue is concentrated in a single geographic region, which increases its exposure to local economic and regulatory risks. The company does not report revenue by business segment, making it difficult to assess the performance of different product lines or therapeutic areas.

The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The capital expenditure of -43.27 million CNY suggests that the company is not investing in new projects or expanding its operations. The free cash flow of 12.33 million CNY is positive but relatively small, indicating that the company has limited cash available for reinvestment or shareholder returns. The company's operating cash flow of 60.95 million CNY is positive, but it is not sufficient to cover its capital expenditures.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The debt-to-equity ratio of 0.52 indicates that the company is not overly leveraged, but the negative net cash position after subtracting total debt suggests that the company may face liquidity challenges in the short term. The company's risk assessment does not identify any significant dilution risks, and there are no recent filings or transcripts indicating plans for share issuance or other dilutive actions.

Recent events and filings do not provide any new insights into the company's operations or financial performance. The company's latest financial report does not mention any material changes in its business strategy or significant new product launches. The absence of recent news or disclosures suggests that the company is operating in a stable but unremarkable manner.

Hainan Shuangcheng Pharmaceuticals Co Ltd (002693.SZ) has undergone a formal classification update, establishing its primary activity as "Pharmaceuticals & Medical Research" within the broader "Healthcare" economic sector. This structural definition, previously unrecorded in the tracked fields, provides a clearer baseline for analyzing the company's operational focus and industry positioning. Concurrently, the firm’s risk profile has been initialized with specific assessments. Dilution risk is now classified as "low," suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment offers a foundational view of shareholder equity protection. In contrast, liquidity risk has been flagged as "medium." This designation indicates potential constraints or volatility in the company's ability to meet short-term obligations or trade volume, warranting closer monitoring of cash flow dynamics and market depth. These updates collectively refine the analytical framework for Hainan Shuangcheng Pharmaceuticals, moving from an undefined state to a structured profile with defined sectoral and risk parameters. The absence of analyst coverage, index membership, or disclosed top holders in the current data snapshot underscores the need for investors to rely on these newly established fundamental metrics for initial evaluation. [doc:002693.sz-ha-financials]